StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the medical equipment provider’s stock.

See reviews below to learn more or submit your own review. ProAir HFA Inhalers provides respiratory relief of bronchospasm and wheezing through metered-dose inhalers. Developed for asthma and COPD ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...